Ucb Biopharma Sprl

Ucbbiopharma Srl

Ucb Pharma, S.a.

Celltech R&d Limited

Sam Philip Heywood

David Paul Humphreys

Emma Dave

Ralph Adams

Alastair David Griffiths Lawson

Pallavi Bhatta

Gavin Barry Wild

Laura Griffin

Razwan Hanif

Christopher John Le Page

Daniel John Lightwood

Diane Marshall

Laura Hancock

The present disclosure relates to a multi-specific antibody molecule comprising or consisting of a) a polypeptide chain of formula (I): VH—CH—X—V; and b) a polypeptide chain of formula (II): VL-CL-Y—Vand pharmaceutical formulations comprising, for example for use in treatment. The disclosure also provides polynucleotide sequences encoding said multispecific antibody molecules, vectors comprising the polynucleotides and host cells comprising said vectors and/or polynucleotide sequences. There is a provided a method of expressing a multispecific antibody molecule of the present disclosure from a host cell.

Multispecific antibody constructs

The present invention provides method for increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises a) a thermal conversion step of holding the composition comprising the antibody molecule at a temperature in the range 30 to 60&#xb0; C. for a period of at least 1 hour, wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.

Method for increasing the percentage of monomeric antibody Fab-dsFv multimeric species

The present invention provides method of increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises: a) a conversion step of treating the composition with a denaturant selected from urea and/or Guanidine hydrochloride; b) wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.

Method of monomerisation of recombinant antibody molecules

The present disclosure relates to a method of modulating the half-life of a binding domain specific to a serum carrier protein by mutating the sequence and a modulated binding domain specific to a serum carrier protein.

Binding domain or antibody specific to a human serum albumin (HSA)

The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab' fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.

Dual specificity antibody fusions

The present disclosure relates to a multi-specific antibody molecule comprising or consisting of three polypeptides: a) a polypeptide chain of formula (I):(Vxx)Vx-Cx-X-V; and b) a polypeptide chain of formula (II): (Vyy)Vy-Cc) a polypeptide of formula (III):Vwherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region, X represents a linker, V represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region, Vrepresents a variable domain,independently represents 0 or 1, wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired and the variable domains Vx and Vy are paired to form a binding domain and optionally a disulphide bond is present between Vand V, in particular where a disulphide bond is present. The disclosure also extends to pharmaceutical formulation comprising the construct, DNA encoding the constructs and vectors comprising same. The disclosure further extends to a method of expressing the constructs, for example in a host cell and methods for formulating same as a pharmaceutical composition. The disclosure also relates to use of the constructs and formulations in treatment.

Single linker FabFv antibodies and methods of producing same

The present disclosure relates to a multi-specific antibody molecule comprising or consisting of: a) a polypeptide chain of formula (I): VH&#x2014;CH&#x2014;X&#x2014;V; and b) a polypeptide chain of formula (II): VL-CL-Y&#x2014;Vand pharmaceutical formulations comprising, for example for use in treatment. The disclosure also provides polynucleotide sequences encoding said multispecific antibody molecules, vectors comprising the polynucleotides and host cells comprising said vectors and/or polynucleotide sequences. There is a provided a method of expressing a multispecific antibody molecule of the present disclosure from a host cell.

The invention relates to antibody molecules having specificity for TNF alpha, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Antibody molecules which bind TNF alpha

The present invention provides a method for recovering a human VH3 domain-containing antibody in monomeric form. In particular the present invention provides a new method that allows recovery of monomeric human VH3 domain-containing antibodies from a mixture containing monomeric and multimeric forms of the antibody.

Method for protein purification

The present disclosure provides a binding protein comprising: a polypeptide heavy chain comprising: VH-(X)n-VH&#x2014;CH (X)y wherein VHis a first variable domain, VHis a second variable domain, CH is a constant domain, Xrepresents an amino acid or peptide, Xrepresents an Fc region, n is 0 or 1 and y is independently 1 or 2, and a polypeptide light chain comprising: VL-(X)n-VL-C wherein VL1 is a first variable domain, VLis a second variable domain, C is a constant domain, Xrepresents an amino acid or peptide and n is 0 or 1, wherein the heavy chain and light chain are aligned such that VHand VLform a first binding domain, and VHand VLform a second binding domain and wherein: there is a disulfide bond between VHand VL, and/or there is a disulfide bond between VHand VL, and use thereof in treatment.

Disulfide stabilized DVD-Ig molecules

The present disclosure relates to a multi-specific antibody molecule comprising or consisting of three polypeptides: a) a polypeptide chain of formula (I): (Vxx)Vx-Cx-X-V; and b) a polypeptide chain of formula (II): (Vyy)Vy-Cy c) a polypeptide of formula (III): Vwherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region, X represents a linker, V represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region, Vrepresents a variable domain,independently represents 0 or 1, wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired and the variable domains Vx and Vy are paired to form a binding domain and optionally a disulphide bond is present between V and V, in particular where a disulphide bond is present. The disclosure also extends to pharmaceutical formulation comprising the construct, DNA encoding the constructs and vectors comprising same. The disclosure further extends to a method of expressing the constructs, for example in a host cell and methods for formulating same as a pharmaceutical composition. The disclosure also relates to use of the constructs and formulations in treatment.

A multivalent antibody fusion protein which comprises an immunoglobulin moiety, for example a Fab or Fab' fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest, wherein the two single domain antibodies are linked by a disulfide bond. There is also provided particular dual specificity antibody fusion proteins comprising a Fab or Fab&#x2032; fragment and one or more single domain antibodies which may be stabilized by a disulfide bond therebetween.

Growing community of inventors

Slough, United Kingdom

Sam Philip Heywood